upamostat

08/22/2014 - "Recently, a phase II clinical trial using the low-molecular-weight uPA inhibitor WX-671 reported activity in metastatic breast cancer. "
02/20/2018 - "Mesupron, the first-in-class inhibitor of urokinase-type plasminogen activator (uPA) is known to regulate cell proliferation and migration, and is under investigation for the treatment of metastatic breast cancer. "
06/01/2017 - "Synergistic induction of apoptosis by combination treatment with mesupron and auranofin in human breast cancer cells."
09/01/2013 - "Upamostat is currently in clinical development as an anti-metastatic and non-cytotoxic agent against pancreatic and breast cancer. "
06/01/2017 - "In the present study, we showed that the synergism between mesupron and auranofin, a thioredoxin reductase inhibitor, for inducing of apoptosis in MCF-7 human breast cancer cells. "

11/16/2023 - "Upamostat has been studied clinically against several cancers and for outpatient treatment of COVID-19. "
03/01/2023 - "We performed a pilot study of upamostat, a serine protease inhibitor, in outpatients with symptomatic COVID-19 before a pivotal trial. "
03/01/2023 - "A randomized, placebo-controlled pilot study of upamostat, a host-directed serine protease inhibitor, for outpatient treatment of COVID-19."

11/16/2023 - "Upamostat has been studied clinically against several cancers and for outpatient treatment of COVID-19. "
09/01/2013 - "Activation of the anti-cancer agent upamostat by the mARC enzyme system."
06/01/2017 - "Our results demonstrated that mesupron and auranofin significantly lead to inhibition of the cancer cells proliferation; cell cycle arrest at the G1/S phase of the cell cycle, and apoptosis as indicated by caspase 3 activation, poly(ADP-ribose) polymerase cleavage, and annexin V staining. "

03/05/2013 - "Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer."

03/05/2013 - "The most common adverse events considered to be related to upamostat were asthenia, fever and nausea. "